Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024
September 25, 2024 17:00 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference
August 28, 2024 17:00 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
August 08, 2024 16:05 ET
|
Tarsus Pharmaceuticals, Inc
Generated $40.8 million in XDEMVY® net product sales in the second quarter and $65.5 million year-to-date Delivered more than 37,000 bottles of XDEMVY to patients in the second quarter Delivered an...
Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
July 29, 2024 16:30 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus to Participate in Upcoming Investor Conferences
May 29, 2024 17:00 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference
May 09, 2024 17:00 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements
May 08, 2024 16:05 ET
|
Tarsus Pharmaceuticals, Inc
Generated $24.7 million in net product sales of XDEMVY®, an 89% increase over Q4 2023, and delivered approximately 26,000 bottles of XDEMVY to patients Secured multiple commercial payer contracts and...
Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
May 01, 2024 17:00 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
April 23, 2024 08:30 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus to Participate at Upcoming Investor Conferences
March 05, 2024 16:30 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...